|
Ranbaxy receives approval to market RAN(R)-lisinopril in Canada |
|
|
|
23 Oct 2007 |
Ranbaxy Laboratories Limited (RLL), announced today that the Company has received approval in Canada to manufacture and market Ran®-Lisinopril 5, 10 and 20 mg oral tablets from Health Canada, Therapeutic Products Directorate (TPD)
GURGAON, India | October 22, 2007 | Ranbaxy Laboratories Limited (RLL), announced today that the Company has received approval in Canada to manufacture and market Ran®-Lisinopril 5, 10 and 20 mg oral tablets from Health Canada, Therapeutic Products Directorate (TPD). Total brand market for Lisinopril 5, 10, and 20 mg oral tablets in Canada is CAD $46 mil. (IMS-MAT: August 2007).
Lisinopril is indicated for the treatment of hypertension and may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents, and as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis, as well as in the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction, to improve survival.
“We are pleased to receive this approval for RAN®-Lisinopril to expand Ranbaxy’s product portfolio of accessible generic product offerings. The product formulation was developed and data assembled by RLL. RAN®-Lisinopril will be manufactured in Ranbaxy’s cGMP facility located in North Brunswick, New Jersey. RPCI’s Sales Team will be offering product to all classes of trade in all of the Canadian provinces immediately,” said Paul Drake, President, Ranbaxy Pharmaceuticals-Canada Inc. (RPCI), Canada.
Ranbaxy Pharmaceuticals-Canada Inc. (RPCI) based in Mississauga, Ontario, Canada, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India’s largest pharmaceutical company. RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.
Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.
SOURCE: Ranbaxy |
